Front-line High-dose Chemotherapy (HDT) Combined With Rituximab for Adults With Aggressive Large B-cell Lymphoma (DLBCL) : Goelams 074 Trial.
Superiority of HDT with autologous stem cell transplantation (ASCT) in the upfront treatment
of poor-risk DLBCL remains an option for intermediate-high (IH) or high IPI young adults. We
updated results of the prospective trial Goelams 074 to evaluate long-term efficacy and
toxicity in 42 patients who underwent HDT with ASCT.
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
CR rate after 3 high dose chemotherapy courses
safety/efficacy of chemotherapy treatment
Yes
Noel MILPIED, PD MS
Principal Investigator
CHU NANTES/GOELAMS
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
GOELAMS 074
NCT00965289
April 2002
June 2009
Name | Location |
---|